# Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)

> **NCT05546580** · PHASE1 · RECRUITING · sponsor: **Oryzon Genomics S.A.** · enrollment: 50 (estimated)

## Conditions studied

- Acute Myeloid Leukemia, in Relapse
- Acute Myeloid Leukemia Refractory

## Interventions

- **DRUG:** Iadademstat
- **DRUG:** Gilteritinib Oral Tablet

## Key facts

- **NCT ID:** NCT05546580
- **Lead sponsor:** Oryzon Genomics S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-11-14
- **Primary completion:** 2025-11-30
- **Final completion:** 2025-11-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2024-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05546580

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05546580, "Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05546580. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*